专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

WO2017162604A1 METHODS FOR DIAGNOSIS AND TREATMENT OF SOLAR LENTIGO 审中-公开
标题翻译：方法的诊断和治疗太阳能LENTIGO
公开(公告)号：WO2017162604A1
公开(公告)日：2017-09-28
申请号：PCT/EP2017/056591
申请日：2017-03-20
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS XIII PARIS-NORD , UNIVERSITÉ DE FRANCHE-COMTÉ , DERMANCE , CHRU DE BESANÇON , EFS BOURGOGNE FRANCHE COMTE
发明人： LE ROY, Christine , GOOROCHURN, Ranesha , VARIN-BLANK, Nadine , HUMBERT, Philippe , VIENNET-STEINER, Céline
IPC分类号： G01N33/537
摘要： The present invention relates to the diagnosis and treatment of solar lentigo (SL). The inventors established an in vitro model of primary fibroblasts isolated from SL (FL) and perilesional (FS) biopsies, which were collected from a cohort of 10 volunteers. Then, the inventors defined morphological and functional characteristics of both dermal cells. The inventors demonstrated by immunofluorescence studies differential morphological features with FL displaying elongated shape, a thin epidermis, disorganized basement membrane, intense melanin deposition and elongated rete ridges collapsing into the dermis and FS presented flattened morphology. Moreover, both fibroblasts demonstrated distinct functional characteristics with FL exhibiting a lower proliferation rate and migration capacity, senescent-like phenotype as well as a higher ability to secrete KGF, HGF, SCF, IL-13 and TGFβ1. Thus, the present invention relates to a method of identifying a subject having or at risk of having or developing solar lentigo, comprising measuring the expression level of IL-13, TGFβ1, HGF, KGF and SCF. The present invention also relates to an IL-13 inhibitor compound for use in the treatment of solar lentigo.
摘要翻译：本发明涉及太阳黑子（SL）的诊断和治疗。本发明人建立了从SL（FL）和全周（FS）活组织分离的原代成纤维细胞的体外模型，其从10名志愿者的队列收集。然后，发明人确定了两种真皮细胞的形态和功能特征。本发明人通过免疫荧光研究表明，具有显示细长形状，薄表皮，无组织基膜，强烈黑色素沉积和细长突起陷入真皮并且FS呈现扁平形态的FL的差异形态学特征。此外，两种成纤维细胞均表现出不同的功能特征，其表现出较低的增殖速率和迁移能力，衰老样表型以及较高的分泌KGF，HGF，SCF，IL-13和TGFβ1的能力。因此，本发明涉及鉴定具有或有风险患有或发展太阳能鸟的受试者的方法，包括测量IL-13，TGFβ1，HGF，KGF和SCF的表达水平。本发明还涉及用于治疗太阳黑子病的IL-13抑制剂化合物。

IPRDB

热门服务

关于我们

友情链接

联系方式